关键词: 缬沙坦, 腹膜透析, 残存肾功能

Abstract: Objective To explore whether the angiotensinⅡreceptor blocker, Valsartan has a protective effects on residual renal function in patients on CAPD. Methods Thirty-four new peritoneal dialysis patients were enrolled into this study, and were divided into two groups randomly, the subjects on study group were administered 40 to 80 mg Valsartan daily, and the controls were administered antihypertensive agents, except ACE inhibitors and/or ARBs. Patients were followed up, at each clinic visit, serum creatinine, BUN, blood pressure, urine volume, urinary protein excretion, creatinine clearance, residual renal function and Kt/v were measured. Result These patients were followed up (28±13) months, 32 patients completed the study, compared with the initial stage, the urine volume and residual renal function both were decreased, but did not reach the significant level, which on control group, these two parameters all declined significantly, (P＜0.05); the average decline value between the two groups has significant difference, the decline of residual renal function of control group was faster than study group for 2.37 times. Conclusion Valsartan can reduce the rate of decline of residual renal function in patients receiving peritoneal dialysis.

Key words: Peritoneal dialysis, Residual renal function